(Stroke. 2007;38:e1.)
© 2007 American Heart Association, Inc.
Major Ongoing Stroke Trials |
Major Ongoing Stroke Trials
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
The following is a list of major ongoing studies about stroke. Information about other multicenter studies that might be included in this list should be submitted to the Stroke Editorial Office by the Principal Investigator. The list will appear online in the February, June and October issues of Stroke.
Aortic Arch Related Cerebral Hazard (ARCH)
This study is designed to compare the efficacy of warfarin (target INR 2.0 to 3.0) with that of aspirin (75 to 150 mg per day) in combination with clopidogrel (75 mg per day) in the secondary prevention of vascular events in patients with stroke or systemic arterial embolism who are found to have significant atheroma of the aortic arch. Patients will be followed by 4 monthly reviews from randomization to the end of the study. The primary end point is time to one of a composite of recurrent ischemic stroke, intracranial hemorrhage, myocardial infarction, peripheral embolism or vascular death.
Steering Committee: P. Amarenco, G.A. Donnan, S.M. Davis, B.R. Chambers, A. Cohen, G.J. Hankey, E. Jones, C.R. Levi and P. Ravaud.
Contact: Australia: Prof Geoffrey Donnan, Coordination Centre, NSRI, Level 1, Neurosciences Building, Health, 300 Waterdale Road, Heidelberg Heights, Vic 3081, Australia. Phone 61-3-9496-2699. Fax 61-3-9457-2650. E-mail donnan@unimelb.edu.au. Europe: Prof Pierre Amarenco, Department of Neurology and Stroke Centre, Bichat - Claude Bernard University Hospital and Medical School Denis Diderot University - Paris VII 46 rue Henri Huchard, 75018 Paris, France. Phone 33-1-40258726 Fax 33-1-4025-7198. E-mail pierre.amarenco@bch.ap-hop-paris.fr
Location: Australia: Coordination Centre, National Stroke Research Centre, Austin Health, Heidelberg Heights Vic 3081, Australia.